|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0006142,
umls-concept:C0017262,
umls-concept:C0030190,
umls-concept:C0042071,
umls-concept:C0069515,
umls-concept:C0078058,
umls-concept:C0185117,
umls-concept:C0205210,
umls-concept:C0242957,
umls-concept:C0332281,
umls-concept:C0664336,
umls-concept:C0681842,
umls-concept:C1256770,
umls-concept:C1274040,
umls-concept:C1522670,
umls-concept:C2911684
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2006-3-24
|
|
pubmed:abstractText |
Survivin, a novel inhibitor of apoptosis, is one of the most cancer-specific proteins identified to date. In this study we (a) evaluated the association between survivin and HER2, vascular endothelial growth factor (VEGF) and uPA/PAI-1 expression and (b) defined its effect on clinical outcome in a large breast cancer patient cohort.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
pubmed-author:CroweSS,
pubmed-author:DuffyM JMJ,
pubmed-author:KahlertSS,
pubmed-author:KonecnyG EGE,
pubmed-author:MengGG,
pubmed-author:PegramM DMD,
pubmed-author:PodratzK CKC,
pubmed-author:RyanB MBM,
pubmed-author:SlamonD JDJ,
pubmed-author:UntchMM,
pubmed-author:WangH-JHJ
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
597-604
|
|
pubmed:dateRevised |
2011-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:16403812-Breast Neoplasms,
pubmed-meshheading:16403812-Cohort Studies,
pubmed-meshheading:16403812-Female,
pubmed-meshheading:16403812-Humans,
pubmed-meshheading:16403812-Inhibitor of Apoptosis Proteins,
pubmed-meshheading:16403812-Microtubule-Associated Proteins,
pubmed-meshheading:16403812-Neoplasm Proteins,
pubmed-meshheading:16403812-Plasminogen Activator Inhibitor 1,
pubmed-meshheading:16403812-Receptor, erbB-2,
pubmed-meshheading:16403812-Treatment Outcome,
pubmed-meshheading:16403812-Urokinase-Type Plasminogen Activator,
pubmed-meshheading:16403812-Vascular Endothelial Growth Factor A
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1.
|
|
pubmed:affiliation |
School of Medicine and Medical Science, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4, Ireland. Brid.Ryan@ucd.ie
|
|
pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, Non-P.H.S.,
Research Support, Non-U.S. Gov't
|
